Document Detail


Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK).
MedLine Citation:
PMID:  23340516     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Duchenne muscular dystrophy (DMD), a progressive X-linked neuromuscular disorder, has an estimated worldwide incidence of 1:3500 male births. Currently, there are no curative treatments and the mean age of diagnosis is 5 years. In addition, subsequent pregnancies frequently occur before a diagnosis is made in an index case. An 'opt in' screening programme was introduced in Wales in 1990 with the aim to: reduce the diagnostic delay, permit reproductive choice and allow planning of the care of the affected boy. Newborn bloodspots were collected routinely as part of the Wales newborn screening programme. Specific consent was obtained for this test separately from the other tests. During the 21-year period, 369,780 bloodspot cards were received from male infants, of these 343,170 (92.8%) were screened using a bloodspot creatine kinase (CK) assay following parental consent. A total of 145 cases had a raised CK activity (≥250 U/l) and at follow-up, at 6-8 weeks of age, 79 cases had a normal serum CK (false-positive rate 0.023%) and 66 cases had an elevated serum CK. DMD was confirmed in 56 cases by genotyping/muscle biopsy studies, Becker muscular dystrophy in 5 cases and other rarer forms of muscular dystrophy in 5 cases. This long-term study has so far identified 13 false-negative cases. The incidence of DMD in Wales of 1:5136 during this period is lower than that of 1:4046 before commencement of screening in Wales. Screening has reduced the diagnostic delay enabling reproductive choice for parents of affected boys and earlier administration of current therapies.
Authors:
Stuart J Moat; Donald M Bradley; Rachel Salmon; Angus Clarke; Louise Hartley
Related Documents :
7953606 - Varicella-zoster virus infection of the central nervous system in the acquired immune d...
8363446 - Idiopathic granulomatous angiitis of the central nervous system. diagnostic challenges.
16926236 - Eosinophilic vasculitis in an isolated central nervous system distribution.
22811726 - An unusual case of tracheoesophageal fistulae.
20466336 - Diagnosis and management of imported chikungunya fever in taiwan: a case report.
21293256 - Diagnostic value of automated her2 evaluation in breast cancer: a study on 272 equivoca...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-23
Journal Detail:
Title:  European journal of human genetics : EJHG     Volume:  21     ISSN:  1476-5438     ISO Abbreviation:  Eur. J. Hum. Genet.     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-09-19     Completed Date:  2014-05-01     Revised Date:  2014-10-12    
Medline Journal Info:
Nlm Unique ID:  9302235     Medline TA:  Eur J Hum Genet     Country:  England    
Other Details:
Languages:  eng     Pagination:  1049-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Creatine Kinase / blood
Genetic Testing*
Genotyping Techniques
Humans
Infant, Newborn
Male
Muscular Dystrophy, Duchenne / diagnosis*,  enzymology
Neonatal Screening*
Sensitivity and Specificity
Wales
Chemical
Reg. No./Substance:
EC 2.7.3.2/Creatine Kinase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional and genetic characterization of two extremely rare cases of Williams-Beuren syndrome asso...
Next Document:  Humic acids-based one-step fabrication of SERS substrates for detection of polycyclic aromatic hydro...